--- a
+++ b/clusters/3009knumclusters/clust_146.txt
@@ -0,0 +1,873 @@
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving investigational agents at time of registration, or at any time while on study and during the 4 weeks preceding enrollment
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients who are receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Investigational drugs: Patients who are currently receiving another investigational drug are not eligible
+Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Use of any other investigational or study agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients may not be receiving any other investigational agents while on study
+Patients must not currently be receiving any other investigational agents
+Patients must not be receiving any other investigational anti-cancer agents while on study
+Patients may not be receiving any other investigational agents while on study
+Patients must not be receiving or planning to receive any other investigational agents
+Patients may not be receiving any other investigational agents while on study treatment
+Other anticancer agents and investigational agents should not be given while the subject is on study treatment
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed\r\n* CYP2C9 agents: patients who are currently receiving drugs that are moderate to strong inducers or inhibitor of CYP2C9 are not eligible\r\n* P-glycoprotein: patients who are currently receiving drugs that are potent inhibitors of p-glycoprotein are not eligible
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
+Patients who are currently receiving another investigational drug
+Patients who are currently receiving other anticancer agents
+Participants who are receiving or have received any other investigational agents within 14 days of enrollment
+Subject is currently being treated with other investigational agents.
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
+Patients receiving ongoing treatment with any other investigational agents are not eligible
+Patients may not be receiving any other investigational agents
+Participants may not be receiving any other study agents
+Participants may not be receiving any other study agents
+Patients may not be receiving or have received any other investigational agents during/or within 1 month prior
+Participants may not be receiving any other investigational agents; patients may not be receiving any other treatment for their rectal cancer during study participation and within 30 days prior to study treatment
+Participants who are receiving any other investigational agents
+Participants cannot receive treatment with any other investigational agents during protocol therapy
+Participants who are receiving any other investigational agents
+Patients receiving any other investigational agents are ineligible
+Participants who are receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible
+Patients receiving any other investigational agents are excluded
+Subjects who are receiving any other investigational agents
+Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
+Receiving any other investigational agents or any other anti-cancer therapy
+EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients receiving any other investigational agents
+EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents during the proposed treatment cycle.
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patient is receiving any other investigational agents.
+Participants who are receiving any other investigational agents
+Subjects who are currently receiving another investigational drug are not eligible
+Subjects who are currently receiving any other anti-cancer agents are not eligible
+Currently receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients receiving ongoing treatment with any other investigational agents are not eligible
+Participants may not be receiving any other research study agents
+Participants may not be receiving any other study agents for at least 7 days prior to enrollment
+Receiving other investigational agents or not yet completed 30 days since completion of an investigational study
+Subjects may not be receiving any investigational agents within 30 days prior to start of study treatment
+Participants may not be receiving any other investigational study agents or treatment for their cancer
+Receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Currently receiving radiotherapy, biological therapy, or any other investigational agents
+Patients who are receiving any other investigational agents
+Participants who are receiving any other investigational agents.
+Patients receiving any other investigational agents.
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Receiving any other investigational agents
+Patients must not be receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Receiving any other investigational agents for their lymphoma
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+EXCLUSION - TREATMENT: Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks
+Participants who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants who are receiving any other investigational agents within 21 days of the first dose of study drug
+Currently receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible.
+Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible.
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients who are currently receiving anti-platelet agents are not eligible
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients who are receiving any other investigational agents
+Patients receiving any other anticancer or investigational drug therapy
+EXCLUSION CRITERIA FOR REGISTRATION: Currently receiving any other investigational agents or systemic cancer therapy
+Anti-cancer Agents\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Prior treatment with other anti-cancer agents
+EXCLUSION - INFUSION: Currently receiving any investigational agents or radiotherapy within 4 weeks prior to entering the study
+Participants who are receiving any other investigational agents
+TREATMENT EXCLUSION: Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
+Participant receiving any other investigational agents within 30-days of enrollment nor during study participation
+Patients may not be receiving any other investigational agents; (i.e. 28-day washout period from prior investigational drug is required)
+Patients who are receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Receiving any other investigational agents
+Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
+Participants who are receiving any other investigational agents
+Patients receiving any other investigational agents
+Participants may not be receiving any other study agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
+Other investigational agents: ?4 weeks
+Patients who are receiving any other anti-cancer or investigational drug therapy are ineligible
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational therapy
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents are excluded
+Patients receiving any other investigational agents
+Patients may not be receiving any other anti-neoplastic investigational agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other therapeutic investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents, or have received investigational agents within 4 weeks of beginning treatment
+Patients may not be receiving (or received prior to enrollment) any other investigational agents for metastatic disease.
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents for treatment of their kidney cancer
+Patients who are receiving other investigational agents
+Patients who are actively receiving any other investigational agents
+Subjects may not receive any other concomitant investigational agents
+Patients who are receiving any other investigational agents
+Patient must not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants may not be receiving any other study agents
+Patients receiving concurrent investigational chemotherapeutic agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents or other tumor-directed therapy.
+Subjects who are receiving any other investigational agents. Prior immunotherapy, topotecan and temozolomide are allowed
+Patients who are receiving any other investigational agents
+Patients receiving other investigational agents.
+Patients who are receiving any other investigational agents.
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents. A minimum washout period of 28 days is required prior to the initiation of on study treatment.
+Patient is receiving other investigational agents
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents).
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients who are receiving any other investigational agents
+STRATUM A: Participants receiving any other investigational agents
+STRATUM B: Participants receiving any other investigational agents
+STRATUM C: Participants receiving any other investigational agents
+Patients may not be receiving any other investigational agents.
+Currently receiving any other investigational agents
+Patients who are currently receiving another investigational therapy are excluded
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients may not be receiving any other investigational agents for the treatment of their breast cancer
+Currently receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients who are receiving any other investigational agents
+Participants may not be receiving any other investigational agents targeting histiocytosis
+Patients receiving any other investigational agents are ineligible
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair
+Patients who are receiving any other anticancer or investigational agents
+Patients must not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents within 30 days of registration
+Patients must not be receiving any other investigational agents
+Current or anticipated use of other investigational agents
+Patients receiving other investigational agents
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational drug therapy
+Receiving any other investigational agents or any other anti-cancer therapy
+Patients may not be receiving any other investigational agents.
+Currently receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Subjects who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents.
+Patients who are receiving any other investigational agents.
+Patients who are currently receiving or have previously received any other investigational agents within 3 weeks prior to entering the study
+Participants who are currently receiving other anticancer agents.
+Participants who are receiving any other investigational agents, or any other anti-cancer therapy during study treatment
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other anti-neoplastic agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents =< 28 days prior to study treatment
+Participants who are receiving any other investigational agents
+Patients receiving any other investigational agents within 30 days of receiving zydelig
+Patients who are receiving any other investigational agents
+Receiving any other investigational agents, or has received an investigational agent within the last 30 days
+Subjects receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Subjects who are receiving any other investigational agents
+Patients receiving other investigational agents
+Participants who are receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients receiving any concurrent investigational agents
+Patients who are receiving any investigational agents
+Patients who are receiving any other investigational agents or other tumor-directed therapy
+Patients receiving any other investigational agents
+Patients may not be receiving any other investigational agents; a 2 week wash-out period for investigational agents is required before registration
+Subjects may not be receiving any other investigational agents
+Currently receiving any other investigational agents
+Concomitant use of other investigational agents.
+Patients who are receiving any other investigational agents within 28 days before start of study treatment
+Subjects may not be receiving other investigational agents
+Patients may not be receiving any other investigational agents =< 14 days from registration
+Patients who are receiving any other investigational agents or have within the last 28 days
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Subjects receiving any other investigational agents
+Receiving any other investigational agents within 14 days prior to enrollment
+Patients who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients who are receiving any other anticancer agents.
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents; any prior investigational agents must be stopped at least 14 days (2 week washout) prior to registration
+Patients who are receiving any other investigational agents are ineligible
+Patients who are receiving any other investigational agents
+Patients should not have received any other investigational agents within the past 4 weeks
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Subjects receiving other investigational agents
+Patients who are receiving any other investigational agents
+Is currently receiving another investigational therapy
+Currently receiving any other investigational agents
+Patients may not be receiving any other investigational agents for the treatment of non-small cell lung cancer
+Patients are permitted to receive investigational imaging agents while on study
+Patients who are receiving any other investigational agents (with exception of imaging agents)
+Patients who are receiving any other investigational agents; however, prior enrollment on a study using investigational agents is acceptable
+Patients who are receiving any other investigational agents within the preceding 4 weeks
+Patients may not be receiving any other investigational agents
+Currently receiving any other investigational agents or received any within the past 28 days
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Subjects receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients receiving any investigational agents
+Patients receiving any other investigational agents
+Patients who are receiving any other investigational agents, or have received an investigational agent within the past 30 days
+Patients receiving any other investigational agents or immunotherapy
+Patients who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients who are receiving any other investigational agents within the preceding 4 weeks
+Patients receiving any other investigational chemotherapeutic agents within 28 days prior to the first dose of trial treatment
+Subjects receiving any other investigational agents
+Patients who are currently receiving any other investigational agents.
+Patients who are receiving any investigational agents
+Patients who are receiving any investigational agents
+Subjects receiving any other investigational or standard antineoplastic agents
+Patients receiving any other investigational agents or are unable to be treated with doxorubicin, cyclophosphamide, and paclitaxel
+Subjects who are currently receiving any other investigational agents
+Patients who are currently receiving another investigational drug are NOT eligible for either Stratum
+Patients may not be receiving any other investigational agents
+Currently receiving any other investigational agents
+Subjects who are actively receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Subjects receiving any other investigational agents
+Currently receiving investigational agents that are intended as treatments of recurrent GBM.
+Receiving other anti-cancer or investigational therapy during study treatment, apart from those agents specified in the study protocol
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents.
+Currently receiving any other investigational agents
+Currently receiving any investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Currently receiving any other investigational agents
+JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents within 4 weeks of the start of the study treatment.
+Currently receiving any investigational agents
+Patients receiving any other investigational agents and or more that two different chemotherapy regimens for treatment of metastatic disease
+Subjects may not be receiving any other investigational agents or anticancer therapies.
+Currently receiving radiotherapy, biological therapy, or any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents; if patients are currently part of or have participated in any clinical investigation with an investigational drug, the last administration of the investigational study should be at least 1 month prior to dosing
+Patients may not be receiving any other investigational and/or anti-cancer agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy
+Subjects who are receiving any other investigational agents
+Must not be currently receiving any investigational drugs
+Currently receiving any other investigational agents
+Current therapy with any other investigational agents.
+Patients who are receiving any other investigational agents
+Patient may be receiving bone targeted agents
+Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
+Subjects who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Current or anticipated use of other investigational agents
+Investigational agents/therapies
+Patients who are receiving any other investigational agents
+TREATMENT: Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks
+Currently receiving any other investigational agents that are intended as treatments of the relapsed tumor
+Currently receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible.
+Patients who are currently receiving other anti-cancer agents are not eligible.
+Past history of other investigational agents
+Patients may not be receiving any other investigational agents with the intent to treat the disease (imaging agents are acceptable)
+Patients who are receiving concurrent chemotherapy, or who are currently receiving other investigational chemotherapeutic agents or concurrently receiving radiation
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational therapeutic agents
+Subjects may not be receiving any other investigational agents
+Patients who are receiving other investigational therapeutic agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Ongoing use of investigational agents or use of investigational agents within the last four weeks
+Are being treated with other investigational agents.
+Patients may not be receiving any other investigational agents; use of over-the-counter herbal medications will also be excluded
+Patients who are receiving any other investigational agents
+Subjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibited
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Participants may not be receiving any other study agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Subjects receiving any other investigational or standard antineoplastic agents
+Patients who are receiving any other investigational agents
+Currently receiving any investigational agents or received any tumor vaccines within the previous 6 weeks
+Patients may not be receiving any other investigational agents
+Subjects is receiving any other investigational agents for the treatment of prostate cancer
+Patients may not be receiving any other investigational agents
+Subjects must not be receiving any other investigational agents
+Patients receiving any other investigational agents.
+Patients may not be receiving any other investigational agents
+Must not be receiving any other investigational agents within 14 days of first dose of azacitidine (day 7)
+Patients receiving any other investigational agents
+Patients may not be receiving any other investigational agents and/or other therapy for their cancer
+Participants may not be receiving any other study agents, and may not have received any other investigational agents within 6 months prior to study entry
+Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
+Patient must not be receiving any other investigational agents
+Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment
+Patients who are receiving any other investigational agents
+Patients who are receiving any other anticancer or investigational drug therapy are not eligible
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients receiving any other study agents
+Patients who are receiving any other investigational agents
+EXCLUSION CRITERIA FOR REGISTRATION: patients who are receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
+Simultaneous primary invasive cancers or patients currently receiving any other investigational agents at time of study enrollment. Patients may have received investigational agents in the past. No washout time period is required.
+Patient may not be receiving any other investigational drug
+Anticancer Agents: participants who are currently receiving other anticancer agents
+Current receipt of any other investigational agents
+Patients receiving any other investigational agents or anti-cancer agents within 30 days other than mibefradil dihydrochloride, hypofractionated RT, or corticosteroids as described in this clinical protocol during treatment
+Participants may not be receiving any other investigational agents
+Patients must not be currently receiving other anti-cancer agents
+Patients who are receiving any other investigational agents
+Participants who are currently receiving any other investigational agents.
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
+Participants may not have received any other investigational agents in the previous 3 months
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
+Concomitant use of other investigational agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents, or exposure to any investigational drug or placebo within 4 weeks of study treatment
+Patients who are receiving any other investigational agents
+Receiving any other investigational agents within 4 weeks of beginning study treatment
+Currently receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Subjects receiving any other investigational or standard antineoplastic agents
+Patients who have received any other investigational agents within the preceding 4 weeks
+Currently receiving any other investigational agents.
+Patients who are currently receiving another investigational drug
+Patients who are currently receiving other anti-cancer agents
+Patients who are receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Receiving any other investigational agents =< 28 days prior to registration
+Patients receiving any other investigational agents are ineligible
+Participants who are receiving any other investigational agents
+Participants who are receiving any investigational agents are not eligible
+Participants receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Subjects who are receiving any other investigational agents
+Patients receiving any other investigational agents are ineligible
+The subject is receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients who are currently receiving another investigational drug
+Patients may not currently be receiving any other investigational agents for leukemia
+Patients may not be receiving any other investigational agents
+TUMOR BIOPSY SEQUENCING: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
+TREATMENT: Patients who are receiving any other investigational agents; patients on other trials will be eligible as long as they are no longer receiving study treatment
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Current or anticipated use of other investigational agents
+Patients who are receiving any other investigational agents
+Patients must not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Subjects receiving any other investigational agents
+Participants may not be receiving any other investigational agents for treatment of their cancer
+Patients who are currently receiving another investigational drug
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients who are receiving any other biologic, cytotoxic or investigational agents
+Any other investigational agents within the past 4 weeks
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents with the intention to treat their cancer (imaging trials are acceptable)
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
+Subjects may not be receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Ongoing use of any other investigational or study agents
+Participants who are receiving any other investigational agents
+Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
+Patients receiving any other investigational agents
+Receiving other investigational agents
+Patients who are receiving any other investigational agents
+Participants who are receiving any other study or off protocol anti-cancer agents
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents are ineligible
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Current or anticipated use of other investigational agents
+Patients who are receiving any other investigational agents
+Patients who have received any other investigational agents within the last 4 weeks
+Patients may not be receiving any additional investigational agents or radiation therapy
+Patients who are currently receiving another investigational drug are not eligible
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to registration
+PHASE II: Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =< 4 weeks prior to randomization
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients may not be receiving any other investigational agents within 4 weeks of starting the study treatment and during the study period
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are receiving any other investigational agents
+Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll 4 weeks after completion of prior agent)
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents for melanoma
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
+Patients may not be receiving any other investigational agents
+Not currently receiving other investigational drugs
+Current use of any investigational agents
+Patients who are receiving any other investigational agents are not eligible
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Treatment with other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+PHASE II: Patients may not be receiving any other investigational agents while on study
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients must not be receiving any other investigational agents
+Patients currently receiving other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Currently receiving any investigational agents or have received any tumor vaccines within the previous six weeks
+May not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Participants receiving any other investigational agents
+Patients who are receiving any other investigational agents for cancer
+Patients who are receiving any other investigational agents
+Active treatment with any other investigational agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients may not be planning to receive any other investigational agents
+Patients must not be planning to receive other anti-cancer agents including investigational agents while on protocol treatment
+Subject who is receiving any other investigational agents;
+Patients who are receiving any other investigational agents
+Not receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Receiving any investigational agents currently or within 30 days prior to study screening
+Patients must not be receiving any other investigational agents
+Patients may not have received any other investigational agents within 4 weeks of study entry
+Subjects receiving any other investigational agents
+Currently receiving any other investigational agents
+Receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Subjects who are receiving or have received any other investigational agents within 28 days prior to day 1 of treatment in this study
+Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
+Concomitant use of other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Current or anticipated use of other investigational agents
+Receiving any other investigational agents at the time of registration
+Patients who are receiving any other investigational agents
+Patients must not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Use of any other investigational agents
+Currently receiving any investigational agents or have received any tumor vaccines within previous 4 weeks
+Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks
+Patients may not be receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Patients who are currently receiving other anticancer agents are not eligible
+Patients who are receiving any other investigational agents
+Current use of other investigational agents
+Use of investigational agents within 30 days
+Currently receiving any other active investigational agents
+Participants who are receiving any other investigational agents after ASCT
+Subjects receiving any other investigational agents
+Patients may not be receiving any other investigational agents\r\n* Note: a wash-out period of 2 weeks prior to registration is required for any patient to be enrolled in the study
+Participants may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
+Patients may not be receiving any other investigational agents within 2 weeks prior to registration
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patient receiving any other investigational agents
+Patients may not be receiving any other investigational cancer-directed agents
+Actively receiving any investigational agents
+Patients receiving any other investigational agents within 30 days prior to the first dose of trial treatment
+Participants who are receiving any other investigational agents within 14 days before the first dose of study drug
+Participants may not be receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other anti-cancer or investigational drug therapy are excluded
+Use of any other investigational agents
+Currently receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Patients receiving other investigational agents
+Patients receiving any other investigational agents or any additional anti-cancer agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Subjects receiving other investigational agents are not eligible
+May not be receiving any other study agents
+Patients may not be receiving any other investigational agents; patients cannot be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy for the purposes of anti-cancer treatment
+Participants may not be receiving any other study agents
+Patients who are receiving any other investigational agents
+Currently receiving investigational agents
+Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
+Patients may not be on any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+PHASE II: Participants may not be receiving any other investigational agents
+Participants may not be receiving any biologics or investigational agents within 3 weeks
+Patients who are receiving any other investigational agents or who have received pomalidomide in the past
+Patients receiving other anti-neoplastic agents are excluded
+Subjects may not be receiving any other investigational agents
+Participants receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients should not be receiving any other investigational agents
+Ongoing therapy with other investigational agents. Patients may not be receiving any other investigational agents.
+Participants who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy
+Participants receiving any other study agents
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
+Participants may not be receiving any other investigational anticancer agents
+Participants may not be currently receiving any other experimental agents
+Currently receiving any other investigational agents that are intended as treatments of GBM
+Participants may not be receiving any other study agents
+Patients receiving any other investigational agents for cancer treatment
+Patients may not be receiving any other investigational agents while on study treatment
+Participants may not be receiving any other study agents
+Participants may not be receiving any other study agents.
+Patients who are currently receiving any other investigational agents.
+Participants may not be receiving any other study agents
+Patients may not be receiving any other investigational agents
+Participants may not be receiving any other study agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents while on study
+Patient receiving any other investigational agents
+Patient must not be receiving any other investigational agents
+Patients who are receiving any investigational agents
+Patients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than androgen deprivation
+Patients currently receiving other investigational drugs are not eligible
+Patient must not be receiving any other investigational agents
+Currently receiving any investigational agents or registration on another therapy based trial
+Patients who are receiving any investigational agents.
+Current or anticipated use of other investigational agents
+Patients may not be receiving any other investigational agents
+Participants may not be receiving any other study agents
+Patients receiving any other chemotherapy or investigational agents
+Patients who are receiving any other investigational agents
+Participants may not be receiving any other study agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents; any prior investigational products must be stopped at least 14 days (2-week washout) prior to registration
+Currently receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Subjects may not receive any other concomitant investigational agents
+Subjects receiving any other investigational agents
+Participants who are currently receiving any other investigational agents
+Participants may not be receiving any other study agents
+Subjects may not be receiving any other standard or investigational anticancer agents, with the exception of hormonal therapy
+Any investigational agents
+Subjects receiving other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents.
+Participants may not be receiving any other investigational agents
+Receiving any other investigational agents including those for symptom management
+Receiving any other investigational agents currently, or within time limits specified above prior to study day 1
+Participants may not be receiving any other study agents
+Patients receiving any other investigational agents
+Patients receiving other investigational agents
+Patients may not be receiving any other investigational agents nor have received any investigational drug 30 days prior to enrollment
+Participants who are receiving concurrent therapy with other investigational agents
+Patient receiving any investigational or experimental agents other than checkpoint blockade immunotherapy
+Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
+Receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients should not be receiving any other investigational agents
+Patients must not be receiving other investigational agents or concurrent anticancer therapy
+Patients should not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
+Patients who are receiving any other investigational agents or commercial agents with the intent to treat the malignancy
+Patients may not be receiving any other investigational agents
+Receiving any other investigational agents
+Other investigational agents: ?4 weeks
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents for anticancer treatment within 3 weeks of starting study medication
+Patient may not be receiving any other antineoplastic agents
+Currently receiving other anti-cancer agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Patients receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are currently receiving other anti-cancer agents are excluded from this trial
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are currently receiving any other investigational agents
+Receiving any other investigational agents
+Patients may not be receiving any other investigational agents.
+Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)
+Patients receiving any other investigational agents
+Patients must have discontinued immunotherapy or other systemic therapy including investigational agents at least 4 weeks prior to entering the study and have recovered from adverse events due to those agents. Patients must agree to not receive any other investigational agents during study participation.
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents or other medications for the treatment of their malignancy
+Participants who are receiving any other investigational agents
+Patients may not receive any other anti-neoplastic or investigational agents within 3 weeks of study enrollment; patients may not be receiving any other investigational agents during treatment on protocol
+Patients receiving any other investigational agents
+Patients receiving any other investigational anti-cancer agents
+Patients receiving any other investigational agents are ineligible
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Current receiving any other anti-neoplastic investigational agents
+Current therapy with other investigational agents.
+Patients receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are currently receiving other anti-cancer agents are not eligible
+Patients may not be receiving any other investigational agents
+Receiving any other investigational agents or any other anti-cancer therapy
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents or have received immunotherapy
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
+Currently receiving any other investigational agents
+Patients may not be receiving any additional investigational agents or radiation therapy
+Currently receiving any other investigational agents
+Participants receiving any other anti-cancer or investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents within 28 days before start of study treatment
+Receiving any other investigational agents simultaneously or within 3 weeks following ablation procedure
+Participants may not be receiving any other study agents
+Currently receiving any other investigational agents that are intended as treatments of recurrent GBM
+Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
+Patients may not be receiving any other investigational agents; a minimum 4 week “washout” period is required
+Participants may not be receiving any other study agents at the time of first treatment
+Patients should not be receiving any other investigational agents
+Investigational agents/therapies
+Investigational agents within 4 weeks of randomization.
+Participants may not be receiving other investigational agents.
+Patients may not be receiving any investigational agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patient must not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients currently receiving other investigational agents
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents.
+Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
+Patients receiving any other investigational agents are ineligible
+Patients may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Participants may not be receiving any other study agents
+Patients receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Patients planning on receiving other investigational agents while on this study
+Patients receiving other investigational therapies
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents or have received other investigational agents for at least 3 weeks
+Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies except hormonal maintenance treatment for prostate cancer
+Patients who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents within 7 days of registration
+Patients who are receiving any other investigational agents
+Patients who are currently receiving another investigational drug are not eligible
+Currently receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Currently receiving any other investigational agents
+Currently receiving any other investigational agents
+Currently receiving any other investigational medication or therapy
+Participants who are receiving any other investigational agents
+Participants who are receiving any other investigational agents
+Subjects who are receiving any other investigational agents
+All cancer patients receiving chemotherapy agents
+Participants may not be receiving any other study agents
+Patient receiving antiplatelet agents
+Patients currently receiving any other investigational agents;
+Participants who are receiving any other investigational agents
+Participants may not be receiving any other investigational agents within 30 days of enrollment or during this study
+Participants who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents.\r\n* Note: it is acceptable to be on combination therapy including either sorafenib, regorafenib, and/or sunitinib.
+Patients who are receiving any other investigational agents
+Subjects who are receiving any other investigational agents or have received another investigational drug in the last 30 days
+Patients who are receiving any other investigational agents
+Subjects may not be receiving any investigational agents
+Research participants receiving any other investigational agents
+No restrictions on use of other investigational agents
+Patients who are receiving any other investigational agents
+Participants who are receiving any other investigational agents; participants who are receiving standard of care induction therapy on a clinical trial may be eligible after discussion with the overall principal investigator
+Patients receiving any other investigational agents are ineligible
+Participants who are receiving any other investigational agents
+Patients receiving any other study agents
+Patient may be receiving bone targeted agents
+Participants receiving any other investigational agents
+Participants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable
+Current or anticipated use of other investigational agents
+Patient must not be receiving any other investigational agents
+Participants may not be receiving any other investigational agents for treatment of GVHD or underlying disease for at least 7 days
+Patient must not be actively receiving any other investigational agents
+Patients who are receiving other investigational agents will be permitted on study, at the discretion of the principal investigator
+Participants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionary
+Current use of any other investigational agents
+Participants may not be receiving investigational agents
+Receiving any other investigational agents =< 6 months prior to registration
+Receiving any other investigational agents =< 6 months prior to Registration
+Active use of any other investigational agents
+Current use of any other investigational agents
+Participants may not be receiving any other investigational agents
+Receiving any other investigational agents
+Current use of any other investigational agents
+Patients may not be receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Currently receiving investigational agents in a clinical trial
+Participants may not be receiving any other investigational agents
+Currently receiving investigational agents in a clinical trial
+Patients may not be receiving any other investigational agents
+Receiving any other investigational agents
+Receiving any other investigational, anticoagulation, and/or chemotherapy agents
+Participants who are receiving any other investigational agents
+Current use of any other investigational agents
+Participants receiving any other investigational agents
+Participant is receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Participants who are currently receiving any other investigational agents or have received investigational agents within the past 3 months will be excluded
+Participants may not be receiving any other investigational agents within past 3 months
+Participants may not have received any other investigational agents in the previous 3 months
+Participants may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents
+Receipt of any other investigational agents =< 3 months prior to randomization, except innocuous agents with no known interaction with the study agents (e.g., standard dose multivitamins or topical agents for limited skin conditions), at the discretion of the protocol lead investigator at each participating site
+Patients receiving any other investigational agents are ineligible
+Ongoing therapy with other investigational agents
+Patients may not be receiving any other investigational agents
+Participants may not be receiving any other investigational agents during the study
+Participants may not be receiving any other investigational agents
+Participants may not be receiving any other investigational agents
+Receiving any other investigational agents
+Patient may not be receiving any other investigational agents
+Patients who are receiving any other investigational agents (in the past 28 days) or herbal medication (within 1 day)
+Patients must not receive any other investigational agents while on study
+Patients may not be receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Patients should not be taking other investigational agents
+Participants who are receiving any other investigational agents
+Patients may not be receiving any other investigational agents
+Current use of any investigational agents
+Patient must not be receiving an investigational drug
+Patients may not be currently receiving any other investigational agents within 4 weeks of study registration
+Patients receiving any other study agents
+Patients must not currently be using other investigational agents
+Participants receiving other investigational agents
+Participants who are receiving any other investigational agents
+Women who are receiving any other investigational agents
+Patients should not be taking other investigational agents
+Receiving any investigational agents
+Subjects may not be receiving any investigational agents
+Current receipt of any other investigational agents or any additional anti-cancer agents for this or any other disease
+Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 1 day)
+Patients who are receiving any other investigational agents
+Ongoing treatment with any other investigational agents
+Patients receiving any other investigational agents within 4 weeks of starting the study
+Receipt of any other investigational agents or any additional anti-cancer agents
+Patients may not be receiving any other investigational agents
+Donors receiving experimental therapy or investigational agents.
+Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 7 days)
+Patients who are receiving any other investigational agents
+Patients receiving
+Patients who are receiving any other investigational agents
+Patients who are currently receiving another investigational therapy are excluded